Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval

The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world impact of ruxolitinib on OS in patients with MF. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Parasuraman, Shreekant, Yu, Jingbo, Shah, Anne, Kumar, Shambhavi, Xi, Ann, Harrison, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720739/
https://www.ncbi.nlm.nih.gov/pubmed/34625831
http://dx.doi.org/10.1007/s00277-021-04682-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720739/
https://www.ncbi.nlm.nih.gov/pubmed/34625831
http://dx.doi.org/10.1007/s00277-021-04682-x

Ejemplares similares